Targeting the IGF1R/PI3K/AKT Pathway Sensitizes Ewing Sarcoma to BET Bromodomain Inhibitors

Abstract

Inhibitors of the bromodomain and extra-terminal domain (BET) family proteins modulate EWS-FLI1 activities in Ewing sarcoma. However, the efficacy of BET inhibitors as a monotherapy was moderate and transient in preclinical models. The objective of this study was to identify the mechanisms mediating intrinsic resistance to BET inhibitors and develop more effective combination treatments for Ewing sarcoma. Using a panel of Ewing sarcoma cell lines and patient-derived xenograft lines (PDX), we demonstrated that IGF1R inhibitors synergistically increased sensitivities to BET inhibitors and induced potent apoptosis when combined with BET inhibitors. Constitutively activated AKT significantly protected Ewing sarcoma cells against BET inhibitors, suggesting that IGF1R regulates responsiveness to BET inhibitors mainly through the PI3K/AKT pathway. Although two Ewing sarcoma cell lines were resistant to IGF1R inhibitors, they retained synergistic response to a combination of BET inhibitors and mTOR inhibitors, suggesting that BET proteins, when IGF1R is not functional, cross-talk with its downstream molecules. Furthermore, the combination of a BET inhibitor and an IGF1R inhibitor induced potent and durable response in xenograft tumors, whereas either agent alone was less effective. Taken together, our results suggest that IGF1R and the downstream PI3K/AKT/mTOR kinase cascade mediate intrinsic resistance to BET inhibitors in Ewing sarcoma. These results provide the proof-of-concept for combining BET inhibitors with agents targeting the IGF1R pathway for treating advanced Ewing sarcoma.

IL‐10 induces MC3T3‐E1 cells differentiation towards osteoblastic fate in murine model

“…We also discovered that IGF1R expression decreased in the calluses of mouse fracture samples with injection of agomiR‐7025‐5p. Previous studies demonstrated that abnormal IGF1R expression plays an important role in the pathogenesis of acute lymphoblastic leukaemia, adrenocortical carcinoma, colorectal cancer and Ewing sarcoma . Thus, our findings indicate that the miR‐7025‐5p/IGF1R axis may play an important role in bone metabolism processes including osteoblast differentiation.…”

Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma

“…This work is also limited by using subcutaneous models. Although subcutaneous tumor models have proven to be useful for evaluating molecular mediators of tumor vasculature and novel therapies for the treatment of ES, the findings reported here should be strengthened using orthotopic ES tumors. Additionally, our studies provided a limited number of days of exercise in a nonvariable fashion with controlled settings on a treadmill.…”

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

“…However, activation of IGF-IR/Akt pathway compromises the efficacy of BET inhibitors in Ewing sarcoma. Combined treatment with BET and IGF-IR pathway inhibitors achieves potent and durable response in preclinical models [139]. Furthermore, the enhancer of zeste homolog (EZH2) is a histone methyltransferase that function as a transcriptional repressor.…”